7 results about "Vitamin D Compound" patented technology

A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation can comprise one or both of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 and a stabilizing compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.

The present invention is intended to provide a compound useful to analyze a vitamin D compound. The present invention provides an alkyne compound represented by Formula (I):where in Formula (I), A is a linear carbon chain having an alkynyl group at an end and having a vinyl group at another end; X1 is CH or 13CH; X2 is CHY, CDY, 13CHY, 13CDY, CO, 13CO, C18O, or 13C18O; m is an integer from 1 to 4; when m is 2 or more, X2s are identical or different; Y is H, D, NH2, 15NH2, OH, 18OH, SH, OR, O(CO)R, OSO3H, OSO3Na, or a sugar substituent; when Formula (I) contains two or more Ys, Ys are identical or different; R is an alcohol protective group, an alkyl group, an alkenyl group, or an aryl group; X3 is C or 13C; and at least one selected from the group consisting of X1, X2(s), and X3 is modified with a stable isotope D, 13C, 18O, or 15N.

Pediatric and modified release dosage forms of vitamin D compounds, and methods of making and using the same, are disclosed. 20 24 20 28 77 01 M ay 2 02 4 A B S T R A C T 2 0 2 4 2 0 2 8 7 7 0 1 M a y 2 0 2 4

A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation can comprise one or both of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 and a stabilizing compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.

The present invention relates to stabilized modified release vitamin D formulations and methods of administering the same. A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation comprises one or both of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 and a cellulose compound. The stabilized formulation exhibits a stable dissolution profile after exposure to storage conditions and demonstrates improved pharmacokinetic parameters compared to unstabilized formulations.

The invention discloses a starch-based gel carrier for collaborative delivery of vitamin D-calcium and a preparation method thereof. According to the invention, calcium ions and vitamin D nutrients are delivered by preparing a starch-based gel carrier, and the release of the carrier in a simulated in-vitro stomach and intestine digestion stage is determined. The starch-based gel carrier prepared by the invention can realize targeted release of calcium ions and vitamin D in an intestinal digestion stage, and is relatively low in cost and simple in process. By taking common corn starch and sodium laurate as examples, after a starch-sodium laurate compound and a starch-vitamin D compound suspension are added into nano calcium carbonate, formation of gel is induced in situ, and slow release of calcium ions and vitamin D in a gastric digestion stage and rapid release of calcium ions and vitamin D in an intestinal digestion stage are realized. The gel carrier can realize protection of vitamin D in a stomach digestion stage and targeted release of vitamin D in an intestinal digestion part, and can effectively improve absorption of vitamin D by a human body so as to assist absorption of calcium ions by the human body.

This application relates to a liquid chromatography-tandem mass spectrometry (LC-MS / MS) system, comprising a sample preparation module, a liquid chromatography module, and a mass spectrometry detection module. The sample preparation module is configured to pre-treat the sample. The liquid chromatography module includes at least one shared chromatography column configured to elute the pre-treated sample for vitamin D detection to separate vitamin D compounds, and also configured to elute the pre-treated sample for steroid detection to separate steroids. The mass spectrometry detection module is configured to perform mass spectrometry detection on the sample eluted by the liquid chromatography module. The elution of both detections can be performed on the same shared chromatography column, eliminating the need for two separate columns, which significantly reduces instrument modularity costs compared to existing solutions.